Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

BACKGROUND: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Kerry, Hölscher, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352246/
https://www.ncbi.nlm.nih.gov/pubmed/22443187
http://dx.doi.org/10.1186/1471-2202-13-33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352246/
https://www.ncbi.nlm.nih.gov/pubmed/22443187
http://dx.doi.org/10.1186/1471-2202-13-33

Ejemplares similares